Larissa van Golen
Nuclear Medicine Phsyicist The Netherlands Cancer Institute
Seminars
Tuesday 11th November 2025
An Update on ProstACT Global: Comparing Standard of Care With or Without 177Lu-DOTA-Rosopatamab
9:00 am
- Evaluating the impact of adding 177Lu-DOTA-Rosopatamab to standard care in PSMA-positive mCRPC
- Assessing the safety and effectiveness of 177Lu-DOTA-Rosopatamab with androgen inhibitors or taxanes
- Exploring new therapeutic strategies for advanced prostate cancer using 177Lu-DOTA-Rosopatamab
